An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma

PHASE4CompletedINTERVENTIONAL
Enrollment

114

Participants

Timeline

Start Date

February 26, 2019

Primary Completion Date

August 4, 2020

Study Completion Date

January 25, 2023

Conditions
Advanced Follicular Lymphoma
Interventions
DRUG

Obinutuzumab

Obinutuzumab 1000 mg IV infusion, administered on Day 1, 8 and 15 during Cycle 1, and on Day 1 of subsequent cycles, for 6-8 cycles. Each cycle is 21 or 28 days long depending on the chemotherapy regimen allocated. Maintenance obinutuzumab monotherapy in patients who achieve at least a partial response, after induction therapy will be administered a dose of 1000 mg once every 8 weeks for 2 years or until disease progression (whichever occurs first).

DRUG

Bendamustine

Bendamustine will be administered on Days 1 and 2 for Cycles 1-6 at a dose of 90 mg/m2/day, for six 28-day cycles.

DRUG

Cyclophosphamide

Cyclophosphamide 750 milligrams per square metre (mg/m\^2), administered intravenously (IV) on Day 1 of each 21-day cycle, for six cycles for CHOP treatment or eight cycles for CVP treatment.

DRUG

Doxorubicin

Doxorubicin 50 mg/m\^2 IV, administered on Day 1 of each 21-day cycle, for six cycles.

DRUG

Prednisone/Prednisolone/Methylprednisolone

Prednisone 100 mg (or equivalent prednisolone or methylprednisolone), administered orally on Days 1-5 of each 21-day cycle, for six cycles for CHOP treatment or eight cycles for CVP treatment.

DRUG

Vincristine

Vincristine 1.4 mg/m\^2 (maximum 2 mg) IV, administered on Day 1 of each 21-day cycle, for six cycles for CHOP treatment or eight cycles for CVP treatment.

Trial Locations (33)

11009

Hospital Universitario Puerta del Mar; Servicio de Hematologia, Cadiz

22081

OncoResearch Lerchenfeld GmbH, Hamburg

23562

Onkologische Schwerpunktpraxis Lübeck, Lübeck

28046

Hospital Universitario la Paz; Servicio de Hematologia, Madrid

30008

Hospital General Universitario J.M Morales Meseguer; Servicio de Hematología, Murcia

50937

Klinik der Uni zu Köln; I. Med. Klinik, Cologne

60596

Universitätsklinikum Frankfurt; Medizinische Klinik II; Onkologie, Frankfurt

78731

Texas Onc-Central Austin CA Ct, Austin

Texas Oncology Cancer Center, Austin

80303

Rocky Mountain Cancer Center; Medical Oncology, Boulder

84036

MVZ Dr. Vehling-Kaiser GmbH; Onkologische Praxis, Landshut

87401

San Juan Oncology Associates, Farmington

20817-1915

American Oncology Partners of Maryland, PA, Bethesda

07932

Summit Medical Center, Florham Park

97401-8122

Willamette Valley Cancer Ctr - 520 Country Club, Eugene

60115-281

NOHC - Núcleo de Oncologia e Hematologia do Ceará, Fortaleza

90035-903

Hospital das Clinicas - UFRGS, Porto Alegre

17210-120

Hospital Amaral Carvalho, Jaú

09113

Klinikum Chemnitz gGmbH, Klinik für Innere Medizin III, Hämatologie und Onkologie, Chemnitz

06847

Städtisches Klinikum Dessau, Dessau

260-8717

Chiba Cancer Center, Chiba

060-8648

Hokkaido University Hospital, Hokkaido

650-0047

Kobe City Medical Center General Hospital, Hyōgo

589-8511

Kindai University Hospital, Osaka

104-0045

National Cancer Center Hospital, Tokyo

135-8550

The Cancer Institute Hospital of JFCR, Tokyo

3318 AT

Albert Schweitzer Ziekenhuis - loc Dordrecht, Dordrecht

9728 NT

Martini Ziekenhuis, Groningen

01009

Hospital De Txagorritxu; Servicio de Hematologia, Vitoria-Gasteiz

08003

Hospital del Mar; Servicio de Hematologia, Barcelona

CF14 4XW

University Hospital of Wales, Cardiff

PO6 3LY

Portsmouth Hospitals NHS Trust - Queen Alexandra Hospital, Portsmouth

TR1 3LQ

Royal Cornwall Hospital, Truro

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT03817853 - An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma | Biotech Hunter | Biotech Hunter